INO-5401
Biologic
Inovio PharmaceuticalsINO-5401 is one of 81 biologic programs targeting Glioblastoma. It is currently in development.
2
Indications
3
Total Trials
2
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
514 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Gleevec
NovartisPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 3
Scemblix
NovartisPhase 3
Lexapro
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Paraplatin
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
Urothelial Carcinoma1 trial
BRCA1/2 Mutation1 trial
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
Active, not recruiting·—·Phase 1·NCT04367675·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INO-5401. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company